Moxetumomab pasudotox

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMoxetumomab pasudotox
Drug Alias Name帕舒托-莫塞妥莫单抗Moxetumomab pasudotox-tdfkMoxetumomabum pasudotoxumLumoxitiHA-22 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > Protein drugs > Toxin
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLymphoma, Non-HodgkinLymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[7] 
Global Approved IndicationsLeukemia, Hairy Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/09/13
Country/TerritoryCanadaUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesInnate Pharma
Inactive CompaniesMedimmune LlcAstrazeneca AbThe University Of Texas MD Anderson Cancer Center
Active IndicationsLeukemia, Hairy Cell
Inactive IndicationsLymphoma, Non-HodgkinLymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[6] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG